[Clinical study of sustained release cephalexin (S-6436, S-6437) in dermatology (author's transl)].
S-6436 or S-6437 was orally administered to 30 patients with bacterial infections including some patients with secondary infections. The following results were obtained: 21 patients had excellent effect, good 5, fair 2 and poor 2. The effectiveness was 86.7%. One gram (potency)/day of sustained release cephalexin was given to most of the patients divided into 2 doses after breakfast and dinner. This b.i.d. regimen was popular among outpatients as well. Staph. aureus isolated from 73.3% of the patients disappeared. Overall bacteriological effectiveness was 72.2%. In only 2 patients, side effects were observed. One had a mild pain in stomach and the other had aggravation of itching in complication of eczema. No abnormalities in laboratory studies which were conducted in some patients were found.
D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D002506:Cephalexin / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology
D003692:Delayed-Action Preparations; D002506:Cephalexin